Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 78Neoplasm Metastasis 16Neoplasms 9Breast Neoplasms, Male 9Brain Neoplasms 6Urinary Bladder Neoplasms 5Ovarian Neoplasms 5Head and Neck Neoplasms 4Colorectal Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Prostatic Neoplasms 3Lung Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma, Ovarian Epithelial 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Pancreatic Neoplasms 2Neuroma, Acoustic 2Neurofibromatosis 2 2Inflammatory Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Ductal, Breast 2Salivary Gland Neoplasms 1Recurrence 1Prolactinoma 1Pituitary Neoplasms 1Patient Compliance 1Neuroectodermal Tumors, Primitive 1

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2 Positive Esophagogastric Cancer × Lapatinib × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡